Of those with cardiovascular disease – the number one killer of women in the U.S. – women fared worse than men in 11 out of 11 clinical metrics. Use of cholesterol reducing medication in the presence of coronary artery disease was seen in only 59 percent of women, compared with 71.5 percent of men. Regarding use of beta blockers following a heart attack, 63 percent of women used the medications, compared to 69 percent of men.
"Despite all the advances in medicine over the last century, we have a long way to go in reducing these needless disparities in women's health care," said
, President and CEO of Society for Women's Health Research. "We need to emphasize more research on women from the very beginning of the drug discovery process, as well as commit to understanding all the factors that affect her adherence to medications for the long-term."
Bridging the Gender Gap in Medication Management
Although women have demonstrated higher utilization for preventive care services, such as cholesterol monitoring, colon cancer screening and immunizations, they are falling short when it comes to treating conditions via medication management.
Through its Women's Health Therapeutic Resource Center (TRC), Medco specialist pharmacists are able to identify adherence issues and omissions in care among patients, then work with physician and patients to resolve the issues and reduce gaps in care.
About the Society for Women's Health Research
The Society for Women's Health Research (SWHR), a national non-profit organization based in
, is widely recognized as the thought leader in women's health research, particularly how sex differences impact health. SWHR's mission is to improve the health of all
advocacy, education and research. Visit SWHR's website at
for more information.
The Organization for the Study of Sex Differences (OSSD) is a flagship program of the Society for Women's Health Research (SWHR), launched in 2006 to promote scientific research on sex differences. Visit OSSD's website at
for more information.
Medco Health Solutions, Inc. (NYSE: MHS) is pioneering
world's most advanced pharmacy
® and its clinical research and innovations are part of
Medco making medicine smarter™
for millions of Americans.
With more than 20,000 employees worldwide dedicated to improving patient health and reducing costs for a wide range of public and private sector clients, and 2011 revenues of
, Medco ranks 34th on the 2011 Fortune 500 list and is named among the world's most innovative, most admired and most trustworthy companies.
For more information, go to
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the risks and uncertainties that affect our business, particularly those mentioned in the Risk Factors section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.